Last modified: January 2, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
About Us
Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for treatment of neuroinflammatory diseases such as Multiple Sclerosis, Alzheimer’s Disease, and Traumatic Brain Injuries. Each of these disorders has a pharmacogenomic linkage to the apolipoprotein E (APOE) protein and people with the ?4 allele typically suffer worse outcomes. brainBased on these findings, scientists from Duke University created novel APOE-based compounds that have potent anti-inflammatory and neuroprotective activities.
Cognosci has purchased all rights to these compounds from Duke and has performed extensive lead optimization and preclinical development programs and is now poised to enter human clinical trials. Optimized compounds have been shown to be efficacious in predictive animal models of Multiple Sclerosis, Traumatic Brain Injury, and Rheumatoid Arthritis. Cognosci is currently seeking $12-15 million in Series A venture funding in order to complete final preclinical toxicology studies, Phase I clinical trials, and to initiate Phase II proof of principle trials.
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| Cognosci Job Trends | Cognosci Jobs |
- 15th Annual Life Sciences Venture Forum 2009 - Best Companies (2 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| Cognosci has been added to the Ecosystem. |